Market Overview:
The global idarubicin HCl market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing demand for targeted therapies, and growing focus on research and development (R&D) activities. Based on type, the global idarubicin HCl market is segmented into 99.6% purity and other types. The 99.6% purity segment is expected to account for a larger share of the market in 2018 owing to its high quality and efficacy. Based on application, the global idarubicin HCl market is segmented into oncology and other applications. The oncology segment accounted for a larger share of the market in 2017 due to rising prevalence of cancer across the globe.
Product Definition:
Idarubicin hydrochloride (Aldara) is an anthracycline antibiotic used in the treatment of cancer. It is a DNA-intercalating agent that inhibits topoisomerase II and arrests replication forks, causing double-stranded breaks.
99.6% Purity:
99.6% purity is a very high level of purity, which means that there are no other components present in the final product except for the target compound. Idarubicin HCl is used as an anti-cancer drug and has been gaining importance due to its better performance than conventional drugs in oncology clinical trials.
Other:
Other is also known as Other Drugs or Idarubicin HCl. It is a drug that belongs to the family of medications called as antineoplastic agents. Idarubicin hydrochloride, which is the other name for this medication, has been used in chemotherapy and treatment of certain types of cancer such as lymphoma and leukemia.
Application Insights:
Oncology was the largest application segment in 2017 and accounted for over 60% of total market revenue. Idarubicin is used for the treatment of cancer, either as a single agent or in combination with other drugs. The drug is used to treat various types of cancers such as breast, lung, colorectal and prostate cancer. Increasing incidences of different types of cancers across the globe has led to an increase in demand for idarubicin hydrochloride worldwide.
The use of idarubicin HCl as a single agent therapy has resulted in improved survival rates compared to chemotherapy drugs; this advantage persists despite advances made by oncology medicines manufacturers regarding development cycle time reduction and cost reduction strategies during clinical trials phases. This factor along with growing awareness about less toxic alternative therapies that can still effectively treat various forms & stages cancer patients have driven market growth over recent years (2017-2030).
Regional Analysis:
North America accounted for the largest share of global market in 2017. The presence of key Idarubicin HCl manufacturers and favorable reimbursement policies are some factors contributing to its largest share. For instance, in 2015, Pharmaceutical Research and Manufacturers Association (PhRMA) represented by companies including AbbVie Inc., AstraZeneca, Pfizer Inc., Merck & Co., and Celgene Corporation helped create awareness about idarubicin hydrochloride drug benefits such as improved survival rates in breast cancer patients through their member support program called “I Am A Survivor†which was launched to raise funds for Breast Cancer Awareness Month (BCAM).
Asia Pacific is expected to be the fastest-growing region over the forecast period owing to increasing number of cancer cases due to tobacco smoking or asbestos exposure.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the idarubicin HCl market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths from cancer worldwide. This number is expected to increase to 21 million new cases and 13 million deaths by 2030. This will create a large demand for idarubicin HCl as a treatment for various types of cancers.
- Rising awareness about chemotherapy: There is an increasing awareness among people about chemotherapy and its benefits as a treatment option for various types of cancers. This is driving the demand for idarubicin HCl, which is used in chemotherapy regimens to treat different types of cancers.
- Technological advancements in oncology: The technological advancements in oncology are helping improve the efficacy and safety profile of drugs such as idarubicin HCl used in the treatment of various types of cancers, thereby driving their demand globally.. For instance, targeted therapies that specifically block proteins involved in tumor growth are being developed which are likely to improve outcomes with fewer side effects compared with traditional chemotherapies like idarubicin hydrochloride .This will further boost the demand for this drug during forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Idarubicin HCl Market Research Report
By Type
99.6% Purity, Other
By Application
Oncology, Other
By Companies
Synbias Pharma, Teva API, Zhejiang Hisun Pharmaceutical, DZD(Heze)Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Idarubicin HCl Market Report Segments:
The global Idarubicin HCl market is segmented on the basis of:
Types
99.6% Purity, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Synbias Pharma
- Teva API
- Zhejiang Hisun Pharmaceutical
- DZD(Heze)Pharmaceutical
Highlights of The Idarubicin HCl Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 99.6% Purity
- Other
- By Application:
- Oncology
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Idarubicin HCl Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Idarubicin HCl is a chemotherapy drug used to treat cancer. It works by killing cancer cells.
Some of the key players operating in the idarubicin hcl market are Synbias Pharma, Teva API, Zhejiang Hisun Pharmaceutical, DZD(Heze)Pharmaceutical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Idarubicin HCl Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Idarubicin HCl Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Idarubicin HCl Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Idarubicin HCl Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Idarubicin HCl Market Size & Forecast, 2020-2028
4.5.1 Idarubicin HCl Market Size and Y-o-Y Growth
4.5.2 Idarubicin HCl Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 99.6% Purity
5.2.2 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Idarubicin HCl Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Idarubicin HCl Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 99.6% Purity
9.6.2 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 99.6% Purity
10.6.2 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 99.6% Purity
11.6.2 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 99.6% Purity
12.6.2 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 99.6% Purity
13.6.2 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Idarubicin HCl Market: Competitive Dashboard
14.2 Global Idarubicin HCl Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Synbias Pharma
14.3.2 Teva API
14.3.3 Zhejiang Hisun Pharmaceutical
14.3.4 DZD(Heze)Pharmaceutical
